Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Patients with metastatic melanoma, previously exposed to anti-PD-1 ICI in the adjuvant setting showed significantly lower ORR and shorter PFS to 1L ICI with either Ipi/Nivo or single-agent anti-PD-1 retreatment.

Authors

Institutions

Publication Details

Journal
European Journal of Cancer
Published
2025-03-06
DOI
https://doi.org/10.1016/j.ejca.2025.115339
Citations
2
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Awa A. Gassama, Jasmina Marić-Brozić, Paweł Teterycz, Ana Arance et al.
2 citations
European Journal of Cancer
Cancer Immunotherapy and Biomarkers
2.09
article

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Awa A. Gassama, Jasmina Marić-Brozić, Paweł Teterycz, Ana Arance, Egle Ramelyte, Ralf Gutzmer, Christoffer Gebhardt, John B.A.G. Haanen, Michael Weichenthal, Nethanel Asher, Célèste Lebbé, Shirly Grynberg, Paolo A. Ascierto, Eva Ellebæk, Vanna Chiarion‐Sileni, Dirk Schadendorf, Marc Bender, Christina H. Bruvik Ruhlmann, Friedegund Meier, Charlotte Aaquist Haslund, Caroline Gaudy‐Marqueste, Peter Mohr, Danielle K. DePalo, Elisabeth Livingstone, Iva Gavrilova, Inge Marie Svane, Wilfried Poudroux, Axel Hausschild, Enrique Espinosa, Guy Ben‐Betzalel, Fabio Bertoldo, Selma Ugurel, Eva Muñoz‐Couselo, Dimitrios C. Ziogas, Miguel‐Ángel Berciano‐Guerrero, Sylwia Kopeć, Lidija Kandolf Sekulović, Piotr Rutkowski, Joanna Mangana, Ulrike Leiter, Reinhard Dummer, Helen J Gogas, Caroline Robert, Ronnie Shapira, Anthonie O. van de Velde, Gergana Shalamanova, Louise Mahncke-Guldbrandt, Valerio DelPrete
article en
2 citations

Abstract

Patients with metastatic melanoma, previously exposed to anti-PD-1 ICI in the adjuvant setting showed significantly lower ORR and shorter PFS to 1L ICI with either Ipi/Nivo or single-agent anti-PD-1 retreatment.

European Journal of CancerVol. 220
Hebron University (PS), Military Medical Academy (RS), Inserm (FR), Universität Hamburg (DE), National and Kapodistrian University of Athens (GR), Université Paris Cité (FR), Université Paris-Saclay (FR), Dutch Cancer Society (NL), Aalborg University Hospital (DK), Rabin Medical Center (IL), Hospital Universitario La Paz (ES), Medical University Plovdiv (BG), Odense University Hospital (DK), Institut Gustave Roussy (FR), Saint Louis University Hospital (US), Aarhus University Hospital (DK), Copenhagen University Hospital (DK), The Netherlands Cancer Institute (NL), Moffitt Cancer Center (US), Christian-Albrechts-Universität zu Kiel (DE), Assistance Publique – Hôpitaux de Paris (FR), University Hospital of Zurich (CH), Vall d'Hebron Institut de Recerca (ES), University Medical Center Hamburg-Eppendorf (DE), Istituto Oncologico Veneto (IT), University Hospital Schleswig-Holstein (DE), Hospital Clínic de Barcelona (ES), Essen University Hospital (DE), Sisters of Charity Hospital (HR), University Cancer Center Hamburg (DE), Vall d'Hebron Hospital Universitari (ES), Elbe Kliniken Stade-Buxtehude (DE), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Centre de Recherche en Cancérologie de Marseille (FR), Hôpital Saint-Louis (FR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Centro de Investigación Biomédica en Red de Cáncer (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), University Hospital Carl Gustav Carus (DE), Johannes Wesling Klinikum Minden (DE), Clinical Research Center Kiel (DE), Instituto de Investigación Biomédica de Málaga (ES), Technische Universität Dresden (DE), University of Tübingen (DE), Aalborg University (DK), Ruhr University Bochum (DE), University of Lübeck (DE)
Good health and well-being
Openalex Percentile: Top 14%
Cancer Immunotherapy and Biomarkers
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.